MX2012012502A - Compuestos pirimidinil indol. - Google Patents

Compuestos pirimidinil indol.

Info

Publication number
MX2012012502A
MX2012012502A MX2012012502A MX2012012502A MX2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A
Authority
MX
Mexico
Prior art keywords
indole compounds
pyrimidinyl
pyrimidinyl indole
compounds
cancer
Prior art date
Application number
MX2012012502A
Other languages
English (en)
Inventor
Wei-Guo Su
Jinshui Li
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2012012502A publication Critical patent/MX2012012502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona los compuestos pirimidinil indol como inhibidores novedosos de cinasas para el tratamiento de cáncer y enfermedades inflamatorias.
MX2012012502A 2010-04-27 2010-04-27 Compuestos pirimidinil indol. MX2012012502A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/072225 WO2011134140A1 (en) 2010-04-27 2010-04-27 Pyrimidinyl indole compounds

Publications (1)

Publication Number Publication Date
MX2012012502A true MX2012012502A (es) 2013-01-18

Family

ID=44860753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012502A MX2012012502A (es) 2010-04-27 2010-04-27 Compuestos pirimidinil indol.

Country Status (16)

Country Link
US (1) US8501166B2 (es)
EP (1) EP2563774B1 (es)
JP (1) JP5634596B2 (es)
KR (1) KR20130069641A (es)
CN (1) CN102858764B (es)
AU (1) AU2010351938B2 (es)
BR (1) BR112012027542A2 (es)
CA (1) CA2797428A1 (es)
HK (1) HK1179952A1 (es)
MX (1) MX2012012502A (es)
MY (1) MY159995A (es)
NZ (1) NZ603802A (es)
RU (1) RU2552999C2 (es)
SG (1) SG185056A1 (es)
TW (1) TWI410419B (es)
WO (1) WO2011134140A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
PE20060269A1 (es) * 2004-05-12 2006-05-11 Aventis Pharma Inc Acido 2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino) propionico como inhibidor de la cinasa 1kb
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
AR053114A1 (es) * 2005-01-12 2007-04-25 Aventis Pharma Inc Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds

Also Published As

Publication number Publication date
AU2010351938B2 (en) 2014-10-30
TW201141851A (en) 2011-12-01
EP2563774B1 (en) 2014-03-12
CN102858764B (zh) 2014-08-20
KR20130069641A (ko) 2013-06-26
MY159995A (en) 2017-02-15
CN102858764A (zh) 2013-01-02
NZ603802A (en) 2014-05-30
CA2797428A1 (en) 2011-11-03
WO2011134140A1 (en) 2011-11-03
EP2563774A1 (en) 2013-03-06
RU2552999C2 (ru) 2015-06-10
BR112012027542A2 (pt) 2019-09-24
EP2563774A4 (en) 2013-07-10
JP5634596B2 (ja) 2014-12-03
US20130058892A1 (en) 2013-03-07
JP2013525381A (ja) 2013-06-20
HK1179952A1 (en) 2013-10-11
US8501166B2 (en) 2013-08-06
SG185056A1 (en) 2012-12-28
RU2012149812A (ru) 2014-06-10
TWI410419B (zh) 2013-10-01
AU2010351938A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
HRP20150692T8 (en) Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
IN2012DN03883A (es)
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
NZ700928A (en) Dna-pk inhibitors
MX359418B (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
MX352975B (es) Piridina y derivados de pirazina.
MX355728B (es) Inhibidores de cinasas.
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
GEP20156229B (en) 5-alkynyl-pyrimidines
EA201171367A1 (ru) Винилиндазолильные соединения
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2013007268A (es) Activadores de pkm2 bicíclicos.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MY159995A (en) Pyrimidinyl indole compounds
EA201270727A1 (ru) Пуриновые соединения
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
GB201016442D0 (en) Novel acridine derivatives

Legal Events

Date Code Title Description
FG Grant or registration